Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

04-06-2020(Thu) 03-06-2020(Wed) 02-06-2020(Tue) 01-06-2020(Mon) 29-05-2020(Fri)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
4 Jun, 2020 (Thursday)

            
GENSCRIPT BIO(1548)
Analysis¡G
Genscript Biotech (1548) announced that Legend Biotech, its direct non-wholly owned subsidiary, has applied for the listing of its ADSs on the Nasdaq Global Market. The net proceeds of the Offering, after deducting the estimated underwriting fees and expenses payable by Legend Biotech in connection with the Offering, is estimated to be approximately US$321.9 million which will be used for the clinical development of LCAR-B38M/JNJ-4528, construction of manufacturing facilities, commercialization of LCAR-B38M/JNJ-4528, development of pipeline programs, as well as working capital and other general corporate purposes. The proposed Spin-off is expected to strengthen the operational management ability of both the Remaining Group and the Spin-off Group, where the management teams can focus more effectively on their respective businesses which is expected to enable a more focused development, strategic planning and better allocation of resources. (I do not hold the above stock)
Strategy¡G
Buy-in Price: $17.50, Target Price: $19.30, Cut Loss Price: $16.60


SINO BIOPHARM(1177)
Analysis¡G
The company is a leading company in the Chinese pharmaceutical industry, with a rich product line, focusing on ten therapeutic areas such as liver disease, anti-tumor, analgesia and breathing, and has a wealth of R & D pipeline reserves. Relying on strong R & D capabilities, it is continuously introducing new products, and clinical trials of large quantities of Class 1 new drugs are progressing rapidly (it is estimated that 2 to 3 innovative drugs will be approved for marketing each year after 2021). New varieties will be intensively harvested in the next few years to achieve rapid growth.
Strategy¡G
Buy-in Price: $12.80, Target Price: $15.20, Cut Loss Price: $11.00



Zhongsheng (881.HK) - Cumulative repressed Demand for Car Purchase is Expected to be Gradually Released

Investment Summary

Constant Enhancement of Profitability

Zhongsheng Group's turnover in 2019 increased by 15% yoy to RMB127.03 billion. Due to its outstanding performance of after-sales and other businesses, and the further optimization of its model structure, its operating profit increased by 20% yoy. At the same time, effective inventory management and expense control have stabilized the expense ratio, and ultimately the profit attributable to the parent company reached RMB4.5 billion, increasing by 23.8% yoy. Basic EPS was RMB1.98, dividends were RMB0.4, and the dividend payout rate remained stable at 20%.

The company's profitability increased slightly. The net profit margin increased by 0.26 ppts, and the net profit of a single store increased from RMB11.4-12.7 million to RMB12.5-14.2 million. The total number of 4S dealerships has increased to 360, with 42 new ones, of which 27 were self-built and 15 were acquired. The acquired stores are located in first- and second-tier cities such as Zhejiang, Beijing, Jiangsu and Guangdong. In terms of brand composition, the number of luxury brand dealers reached 208, increasing by 33, and mid- to high-end brands increasing from 9 to 132.

Premium Car's Sales Volume Exceeds Mid- to High-end Cars

The overall domestic auto market continued to decline in 2019, and the structured development trend was obvious, which was reflected in the following aspects: the first- and second-tier cities had the lowest sales volume decline. Automobile consumption presented a trend of regional differentiation, brand differentiation and model level differentiation. In high-tier cities, high-end consumption continued to be stable. Japanese high-end brands and German premium brands were selling well. It is expected that the pattern of differentiation will continue in the future. In 2019, the company's new car sales volume increased by 18.4% to 228,000 units yoy, accounting for 50.04%, up by 3.3 points, surpassing mid- and high-end for the first time, and its revenue share also increased by 1.3 points to 71% yoy.

Proportion of After-sales Service Increased, Contributing Nearly 60% of the Profit

In terms of revenue composition, the revenue from new car sales was approximately RMB106.2 billion, an increase of 13.9%. The revenue from after-sales and boutique business was approximately RMB17.84 billion, an increase of 22.9%. The proportion of revenue from new car sales business to total revenue decreased from 86.5% to 85.6% in 2018, while the proportion of after-sales and boutique business revenue increased from 13.5% to 14.4%.In terms of gross profit contribution, the proportion of gross profit from new car sales business decreased from 23.2% to 20.1%, while the proportion of gross profit from after-sales and boutique business increased from 57.3% to 59.8%; net value-added service revenue was RMB2.89 billion, an increase by 20%, accounting for about 20%. The financial penetration rate increased by 3.4 ppts yoy.

Cumulative repressed Demand for Car Purchase is Expected to be Gradually Released

In 2019, the company tended to be cautious about investment expansion, slowing down the pace of land acquisition and mergers and acquisitions. Capital expenditures decreased significantly by about RMB2 billion, and the interest-bearing debt ratio decreased by 8 ppts. Objectively, it also reduced the financial pressure during the COVID-19 pandemic, providing a guarantee for overcoming difficulties and long-term sustainable development in the future. In response to the pandemic, manufacturers and the government have both launched relief measures, and the company's inventory pressure and cash flow pressure have been eased. At present, the inventory ratio of the company's Japanese brand models is maintained at a low level, and its excellent product portfolio is expected to take the lead in the expected trend of the gradual release of users` car replacement needs in domestic first- and second-tier cities in the future.

Investment Thesis

We expect the company's EPS for 2020/2021 to reach 2.22/2.67 yuan and the target price of HK$45, corresponding to 2020/2021 18/15x P/E (considering its leading position). We gave a accumulate rating. (Closing price as at 29 May)

Financials

Click Here for PDF format...




Recommendation on 4-6-2020
RecommendationAccumulate
Price on Recommendation Date$ 39.800
Suggested purchase priceN/A
Target Price$ 45.000
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2020 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]